Not Just Another Calcinosis Clinical Case
Calcinosis affects 20% to 40% of patients with juvenile dermatomyositis (JDM), and is associated in particular with antinuclear matrix protein 2 (anti-NXP2) antibodies, younger age at disease onset, and persistent disease activity.1-3 Extensive calcinosis beginning in early childhood is rare. No treatment is uniformly effective, although Janus kinase ( JAK) inhibitors have emerged as an option for refractory calcinosis.2,4
Authors
- Oana Moldovan (ORCID: https://orcid.org/0000-0003-0274-4313)
- Raquel Campanilho‐Marques (ORCID: https://orcid.org/0000-0002-1894-8516)
- Ana Teresa Melo (ORCID: https://orcid.org/0000-0002-7904-0683)
- Bianca Paulo Correia (ORCID: https://orcid.org/0009-0002-4541-2386)
Institutions
- University of Lisbon (PT)
- Unidade Local de Saúde de São José (PT)
- Centro Académico de Medicina de Lisboa (PT)
- Unidade Local de Saúde Santa Maria (PT)
Publication Details
- Journal
- The Journal of Rheumatology
- Published
- 2026-11-15
- DOI
- https://doi.org/10.3899/jrheum.2026-0641
- Primary Topic
- Inflammatory Myopathies and Dermatomyositis
- Type
- article
- Field-Weighted Citation Impact
- 0.00